Collaboration

#Advanced Therapies #Collaboration #Eli Lilly #Gene editing #Hearing Loss #Seamless Therapeutics

Lilly’s Seamless gene editing collaboration targets hearing loss

Eli Lilly and Seamless Therapeutics are teaming up to develop and commercialise programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.   The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway.  Under the… Read More

#Business & Investment #News

#Bristol Myers Squibb #Collaboration #Janux Therapeutics #Oncology #Solid tumours

Janux and Bristol Myers Squibb partner on tumour-activated therapeutic

Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement.   Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types.  Janux may receive up to $50… Read More

#Business & Investment #Cancer Research #News

NVIDIA office Paris
#Artificial intelligence (AI) #Collaboration #Drug discovery #Eli Lilly #JP Morgan Healthcare Conference #NVIDIA #Thermo Fisher Scientific

NVIDIA expands drug discovery platform, partners with Lilly

NVIDIA has announced a major expansion of NVIDIA BioNeMo, its open development platform for AI-driven biology and drug discovery, at the JP Morgan Healthcare Conference.  The platform has expanded to include:  New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model  BioNeMo Recipes… Read More

#Business & Investment #News #Trending News

#Acute inflammatory conditions #Autoimmune disease #Bispecific Antibodies #Collaboration #Earendil Labs #Sanofi

Sanofi and Earendil agree $2.56b bispecific antibodies deal

Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programmes.  Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration.  According to the agreement Earendil Labs will receive up to $160 million in upfront… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Collaboration #PRISM BioLab #Talus Biosciences #Transcriptomics

Talus Bio and PRISM BioLab collaborate on TF and PPI targets

Talus Bioscience and PRISM BioLab have agreed to join forces with the aim of accelerating the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets.   The collaboration combines Talus Bio’s regulome profiling and AI-guided drug discovery platform with PRISM’s chemistry platform.  “This collaboration… Read More

#Business & Investment #News

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney disease. Our collaboration… Read More

#Business & Investment #News

#Collaboration #Metabolic diseases #OTR Therapeutics #Zealand Pharma

Zealand and OTR enter strategic collaboration on metabolic therapies

Zealand Pharma and OTR Therapeutics have entered a multi-programme strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases.  The collaboration will combine Zealand Pharma’s experience in obesity and metabolic health with OTR Therapeutics’ oral small-molecule platform.  "The multi-programme collaboration will expand our metabolic health pipeline into oral… Read More

#Business & Investment #News

Bacteria in Petri dishes
#Bacteria #Collaboration #Southwest Research Institute #Trinity University

SwRI and Trinity University to study stable bacterial proteins

Southwest Research Institute (SwRI) and Trinity University have announced plans to study Thermus thermophilus, a thermal bacterium with highly stable proteins.  The plan is to advance scientific understanding of stability mechanisms that could pave the way for advanced treatments for diseases such as Alzheimer’s, amyotrophic lateral sclerosis… Read More

#News

#Artificial intelligence (AI) #Collaboration #Genetics / genomics #NVIDIA

ARC, Mount Sinai and NVIDIA team up to decode the human genome

A collaboration between ARC Innovation at Sheba Medical Center, Icahn School of Medicine at Mount Sinai and NVIDIA will use the power of artificial intelligence (AI) in a bid to better understand the unexplored regions of the genome. The three-year collaboration will see the groups work together to create an… Read More

#Business & Investment #News

T cells
#Adagene #Collaboration #Colorectal cancer #Oncology #T cell engagers #Third Arc Bio

Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers

Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens.   In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide.   Adagene will receive an upfront payment of $5… Read More

#Business & Investment #News

#10x Genomics #Bioscience #Collaboration #SPT Labtech

SPT Labtech and 10x Genomics partner on automated workflows

Manufacturer SPT Labtech has announced a partnership with biotechnology company 10x Genomics to provide automated workflows for single cell research.   The collaboration will allow scientists to scale experiments on 10x’s Chromium Single Cell platform, with planned future expansion to the Visium Spatial platform, by providing plug-and-play protocols on SPT Labtech’s… Read More

#Business & Investment #News

#Collaboration #Immunotherapy #Oncology

French partnership aims to advance immunotherapies

A trio of French organisations across pharma, government and academia have partnered with the aim of accelerating immunotherapy for oncology, inflammation, and autoimmunity research. OSE Immunotherapeutics, Inserm Transfert and Nantes University have signed a strategic partnership which will combine academic research with industrial expertise to bring more immunotherapies… Read More

#Cancer Research #News

Japanese flag
#BioIndustry Association #Biotechnology #Collaboration #Japan Bioindustry Association

UK and Japan partner to advance biotech

The UK BioIndustry Association (BIA) and Japan Bioindustry Association (JBA) have signed a deal that aims to connect the two countries’ life sciences and biotech sectors to advance medical innovation and commercialise engineered biology. The countries memorandum of understanding (MOU) aims to establish new links between British and Japanese biotech… Read More

#Business & Investment #News

University of Birmingham
#Autoimmune disease #Collaboration #Funding #Immune system #Osaka University #University of Birmingham #University of Oxford

Birmingham Uni and Nobel winner secure inflammation funding

Scientists and clinician-scientists at the University of Birmingham will lead a major research programme to transform the treatment of autoimmune diseases by halting chronic inflammation at its source.  Backed by a £3.83 ($5.1) million Wellcome Discovery Award, Birmingham researchers will join 2025 Nobel Prize winner Professor Shimon… Read More

#News

#Biotech #CDMO #Collaboration #Drug development

How speed and clarity decide biotech’s winners 

Dr Thomas Meins, General Manager of WuXi AppTec’s subsidiary Crelux in Munich, Germany discusses how agile collaboration helps innovators adapt and succeed. Every biotech project begins with a vision, an idea with the potential to turn science into impact. But a vision alone is not enough. Turning that idea into… Read More

#Exclusive Content

#AbbVie #Brain disease #Collaboration #Nxera Pharma

Nxera Pharma receives $10 million from collaboration with AbbVie

Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced.  Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. Read More

#Business & Investment #News